CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $793 | -40.8% | 28,830 | -27.0% | 0.04% | -36.2% |
| Q2 2023 | $1,340 | +57.6% | 39,480 | +67.0% | 0.06% | +45.0% |
| Q1 2023 | $850 | +129.7% | 23,636 | +185.0% | 0.04% | +100.0% |
| Q4 2022 | $370 | -99.9% | 8,293 | -64.0% | 0.02% | -48.7% |
| Q3 2022 | $647,000 | +27.4% | 23,033 | +22.2% | 0.04% | +2.6% |
| Q2 2022 | $508,000 | +6.7% | 18,845 | +34.8% | 0.04% | +22.6% |
| Q1 2022 | $476,000 | +71.2% | 13,985 | +94.6% | 0.03% | -11.4% |
| Q4 2021 | $278,000 | -36.8% | 7,185 | -11.9% | 0.04% | -40.7% |
| Q3 2021 | $440,000 | +129.2% | 8,155 | -25.7% | 0.06% | +7.3% |
| Q4 2020 | $192,000 | -71.3% | 10,980 | -75.6% | 0.06% | -74.1% |
| Q3 2020 | $668,000 | – | 45,070 | – | 0.21% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |